Kane Biotech Stock Debt To Equity
| KNBIF Stock | USD 0.08 0.0003 0.39% |
Kane Biotech fundamentals help investors to digest information that contributes to Kane Biotech's financial success or failures. It also enables traders to predict the movement of Kane OTC Stock. The fundamental analysis module provides a way to measure Kane Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kane Biotech otc stock.
Kane |
Kane Biotech OTC Stock Debt To Equity Analysis
Kane Biotech's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Kane Biotech Debt To Equity | 7.12 % |
Most of Kane Biotech's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kane Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Kane Biotech has a Debt To Equity of 7.119%. This is 86.7% lower than that of the Healthcare sector and 63.23% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 85.38% higher than that of the company.
Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Kane Fundamentals
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Shares Owned By Insiders | 26.82 % | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 1.61 M | |||
| Gross Profit | 568.44 K | |||
| EBITDA | (4.25 M) | |||
| Net Income | (4.6 M) | |||
| Cash And Equivalents | 2.53 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 7.12 % | |||
| Current Ratio | 0.67 X | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (2.29 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 18 | |||
| Beta | 0.19 | |||
| Market Capitalization | 10.45 M | |||
| Total Asset | 6.13 M | |||
| Z Score | 5.4 | |||
| Net Asset | 6.13 M |
About Kane Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kane Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kane Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kane Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.